Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Shanghai Henlius Biotech
NRG Oncology
Shanghai Jiao Tong University School of Medicine
SWOG Cancer Research Network
Ukrainian Society of Clinical Oncology
West German Study Group
Australasian Gastro-Intestinal Trials Group
Shengjing Hospital
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Shanghai JMT-Bio Inc.
Zhongnan Hospital
Cancer Research Antwerp
Fudan University
Shanghai JMT-Bio Inc.
Shanghai University of Traditional Chinese Medicine
Shanghai Jiao Tong University School of Medicine
SWOG Cancer Research Network
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Medical Research Council
Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
Spanish Oncology Genito-Urinary Group
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Shengjing Hospital
Second Affiliated Hospital, School of Medicine, Zhejiang University
Merck Sharp & Dohme LLC
Second Affiliated Hospital, School of Medicine, Zhejiang University
SWOG Cancer Research Network
Blokhin's Russian Cancer Research Center
Biocad
Karolinska University Hospital
Air Force Military Medical University, China
Lumos Pharma
Hebei Medical University Fourth Hospital
Krankenhaus Nordwest
Qingdao Central Hospital
AIO-Studien-gGmbH
Shandong Cancer Hospital and Institute
Peregrine Pharmaceuticals
Tianjin Medical University Cancer Institute and Hospital
Proton Collaborative Group
Shanghai Zhongshan Hospital
Synta Pharmaceuticals Corp.
Tehran University of Medical Sciences
National Cancer Institute (NCI)
Medical University of Lublin
Sanofi
Sanofi
Novacea